Carl R. Alving
- Virology top 0.5%
- HIV Research and Treatment 57
- Immunology top 0.2%
- Immunotherapy and Immune Responses 62
- Complement system in diseases 25
- Immune Cell Function and Interaction 20
- Pharmaceutical Science top 0.5%
- Biomaterials top 1%
- Endocrinology top 1%
-
- Monoclonal and Polyclonal Antibodies Research 54
-
- Lipid Membrane Structure and Behavior 49
- RNA Interference and Gene Delivery 44
- Glycosylation and Glycoproteins Research 27
Carl R. Alving
257 papers receiving 10.1k citations
Peers
Comparison fields: 5 of 144
- Virology 1.2k
- Immunology 4.4k
- Pharmaceutical Science 748
- Biomaterials 1.1k
- Endocrinology 403
Countries citing papers authored by Carl R. Alving
This map shows the geographic impact of Carl R. Alving's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl R. Alving with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl R. Alving more than expected).
Fields of papers citing papers by Carl R. Alving
This network shows the impact of papers produced by Carl R. Alving. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl R. Alving. The network helps show where Carl R. Alving may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Carl R. Alving, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 2 | |
| 2 | 2017 | 38 | |
| 3 | 2014 | 43 | |
| 4 | 2012 | 16 | |
| 5 | 2011 | 6 | |
| 6 | 2010 | 4 | |
| 7 | 2008 | 59 | |
| 8 | 2005 | 51 | |
| 9 | 2003 | 59 | |
| 10 | 2002 | 14 | |
| 11 | 1996 | 38 | |
| 12 | 1996 | 14 | |
| 13 | 1995 | 53 | |
| 14 | Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation. | 1994 | 23 |
| 15 | 1993 | 26 | |
| 16 | 1993 | 23 | |
| 17 | 1992 | 12 | |
| 18 | 1989 | 5 | |
| 19 | 1987 | 22 | |
| 20 | Metabolic fate of liposomal phosphatidylinositol in murine tumor cells: implications for the mechanism of tumor cell cytotoxicity. | 1985 | 12 |
About Carl R. Alving
Carl R. Alving is a scholar working on Virology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 261 papers that have together received 10.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (62 papers), HIV Research and Treatment (57 papers), Monoclonal and Polyclonal Antibodies Research (54 papers), Lipid Membrane Structure and Behavior (49 papers), RNA Interference and Gene Delivery (44 papers), Glycosylation and Glycoproteins Research (27 papers), Complement system in diseases (25 papers) and Immune Cell Function and Interaction (20 papers). The work is most often cited by research in Virology (1.2k citations), Immunology (4.4k citations) and Pharmaceutical Science (748 citations). Carl R. Alving has collaborated with scholars based in United States, Israel and Switzerland. Frequent co-authors include Gary R. Matyas, Mangala Rao, Roberta L. Richards, Nabila M. Wassef, János Szebeni, Gregory M. Glenn, Zoltán Beck, Sándor Sávay, Kristina K. Peachman and Glenn M. Swartz. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.